India Antacids Market Overview, 2031

Key Insights

• According to the research report, "India Antacids Market Outlook, 2031," published by Bonafide Research, the India Antacids Market was valued at more than 543.29 Million in 2025.
• The demand for antacids in India is driven by widespread lifestyle factors, including diet patterns rich in spices and oil, irregular meal times, high stress levels, and rising urban obesity. Surveys and clinical epidemiological studies show that approximately 32% of adults aged 30 to 44 in India encounter frequent acidity and indigestion issues. Among urban populations and older demographic brackets, the prevalence of gastroesophageal reflux symptoms is even higher.
• India features a distinct OTC landscape where single-serve, low-cost effervescent powders (such as sodium bicarbonate paired with citric acid) command massive volume in both urban hubs and rural markets. Market players have innovated with rapid-dissolve tech, sugar-free variants, and localized flavor extensions (such as Jeera, Pudina, and Kachha Aam) to drive accessibility. Brands like Eno (Haleon) and Gas-O-Fast (Mankind Pharma) have transformed fast-acting sachets into high-frequency impulse consumer goods available at neighborhood retail shops (kirana stores) beyond formal pharmacies.
• The clinical treatment approach in India has rapidly shifted from traditional single-salt neutralizers (such as simple aluminum hydroxide or magnesium trisilicate) toward multi-action combination therapies. Modern Indian OTC and ethical prescription antacid brands increasingly incorporate simethicone (to alleviate concurrent gas and bloating) alongside sodium alginate and magnesium carbonate. Formulations like Digene, Gelusil, and Polycrol emphasize creating a protective gastric raft that prevents reflux while buffering hyperacidity.

Market Outlook

• Lower-tier towns and rural regions represent the next major growth horizon. Pharmaceutical firms are aggressively strengthening their OTC distribution networks, leveraging sachet pricing models (often priced under ₹10 to ₹15 per sachet) and expanding non-pharmacy retail presence to capture first-time self-medication consumers
• Consumers are increasingly adopting herbal and Ayurvedic digestive remedies to avoid long-term reliance on synthetic chemical neutralizers. Next-generation product development in India is focusing on hybrid OTC solutions that combine fast-acting antacid salts with traditional botanicals like Yashtimadhu (liquorice), Amla, and Shatavari for mucosal healing and stomach lining protection.
• The Indian gastrointestinal healthcare and OTC landscape is governed by regulatory guidance from bodies such as the Indian Society of Gastroenterology (ISG) and the Organisation of Pharmaceutical Producers of India (OPPI), with market supply led by domestic and international leaders including Abbott India (Digene), Pfizer India (Gelusil), Haleon (Eno), Mankind Pharma (Gas-O-Fast), Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Cipla.

Market Dynamics

Driver: Rising lifestyle-related digestive discomfort and self-medication
A major driver for India's antacids market is the increasing incidence of indigestion, heartburn and acidity associated with irregular eating patterns, eating outside the home, late dinners, frequent snacking and busy work schedules. Euromonitor reports that in 2025, digestive-remedy demand was supported by these lifestyle changes as well as increasing awareness of gut health among urban and semi-urban consumers. This is particularly relevant for antacids because they are readily available OTC products and are commonly used for immediate, short-term symptom relief.
Challenge: Price sensitivity and competition from home remedies
A key challenge is that Indian consumers are highly price-sensitive, while antacids compete not only with other branded OTC products but also with home remedies and dietary changes. Euromonitor expects affordable pricing and micro-packaging to remain important for mass-market appeal, while renewed consumer preference for home remedies and dietary correction could limit frequent OTC antacid use.
Trend: Shift toward convenient liquid and digital-first OTC purchasing
The Indian antacids market is increasingly moving toward convenient dosage formats and faster-access distribution channels. While tablets remain the largest antacid format, market research identifies liquid antacids as the fastest-growing type segment. At the same time, digestive-remedy distribution is shifting from simple product availability toward immediacy and convenience, with online pharmacies and digital channels becoming more relevant.

Procurement and Industry Impact

• India's pharmaceutical industry has a significant dependence on imported APIs and intermediates. According to India's Department of Pharmaceuticals, the country imported approximately US$4.35 billion of APIs, bulk drugs and drug intermediates across 200 categories in FY2024–25, with China accounting for 73.7% (US$3.20 billion) of these imports. Importantly, the government specifically identifies gastrointestinal disorders among therapeutic segments with high import dependence.
• India is actively trying to reduce API import dependence through the Production Linked Incentive (PLI) scheme and Bulk Drug Parks. As of March 2026, the government reported that domestic manufacturing capacity of approximately 56,800 tonnes per year had been established for 28 of 41 identified critical products under the bulk-drug PLI program.
• ndia's antacid category is fundamentally mass-market and price-sensitive. Euromonitor specifically expects affordable pricing and micro-packaging to be important to digestive-remedy growth, while manufacturers compete across multiple formats and distribution channelsProcurement teams will increasingly focus on API price negotiation, high-volume sourcing, packaging optimization and local contract manufacturing. Small packs can increase affordability and improve distribution reach, but they also make packaging costs more significant as a percentage of the final product cost. Therefore, manufacturers that can reduce packaging and formulation costs without compromising quality are likely to have a competitive advantage.

Segment Analysis

India Antacids Market By Drug Class • Acid neutralizers remain a major component of India's gastrointestinal self-care environment because they provide direct, relatively rapid relief from acidity, heartburn and dyspeptic discomfort. Aluminium hydroxide, magnesium hydroxide and combination preparations are established approaches. India's National Formulary specifically lists aluminium hydroxide + magnesium hydroxide combinations for peptic ulcers, heartburn and dyspepsia, with chewable tablets and suspensions among the listed dosage forms.
• Proton Pump Inhibitors (PPIs) occupy a more sustained acid-suppression position and are particularly relevant when symptoms are frequent or severe. The Indian Society of Gastroenterology recommends antacids and H2-receptor blockers for occasional or mild symptoms, while PPIs are preferred for frequent or severe GERD symptoms. This creates a clear therapeutic distinction between rapid symptomatic relief and longer-duration acid suppression.
• H2 antagonists provide an intermediate treatment approach by reducing gastric acid secretion rather than neutralizing acid already present. Their role is particularly relevant for occasional or mild reflux symptoms. The Indian Society of Gastroenterology specifically includes H2-receptor antagonists among the treatment options for occasional or mild GERD, while reserving PPIs for more frequent or severe symptoms.
• Pro-motility agents represent a specialized segment because they target gastrointestinal movement rather than acid itself. Their potential role is greater when reflux is accompanied by impaired gastric emptying, post-meal fullness or other motility-related symptoms. However, the Indian Society of Gastroenterology notes that prokinetics have a limited proven role in GERD management, restricting their importance compared with conventional antacids and acid-suppressive therapies.
• Combination formulations are particularly relevant in India because consumers frequently seek treatment for overlapping acidity, gas, indigestion and reflux symptoms. The National Formulary of India lists aluminium hydroxide + magnesium hydroxide combinations and notes combinations with ingredients such as simethicone and other agents. This supports multi-symptom positioning and allows manufacturers to differentiate products beyond simple acid neutralization.

India Antacids Market By Dosage Form • Tablets and chewables remain highly suitable for India's self-medication environment because they are portable, easy to administer and do not require measuring equipment. Chewable antacids are particularly convenient for consumers seeking relief after meals or while travelling. The National Formulary of India specifically identifies chewable tablets among dosage forms for aluminium hydroxide + magnesium hydroxide preparations.
• Liquid suspensions provide an important alternative for consumers who have difficulty swallowing tablets or prefer liquid medicines. They also allow manufacturers to combine several active ingredients in one formulation. The Indian National Formulary lists suspension as a dosage form for aluminium hydroxide + magnesium hydroxide and magnesium hydroxide preparations, reinforcing the established role of liquid antacid formulations in India.
• Powders provide a flexible non-tablet format that can be dissolved, dispersed or otherwise prepared before administration. Their appeal comes from convenient portioning and the possibility of rapid preparation. However, because powders require an additional preparation step, moisture-resistant sachets, accurate dosing and clear instructions become important competitive factors.
• Gels and syrups offer smooth administration and can be attractive to consumers who dislike tablets. Gel-based formulations can also support reflux-barrier concepts when alginates are incorporated. In India, liquid and semi-solid formulations can be particularly useful for consumers seeking a more immediately soothing administration experience.
• Gummies and other formats represent an emerging consumer-oriented opportunity rather than a traditional core antacid format. Gummies can improve portability and palatability, but traditional antacid ingredients can require relatively high active quantities, creating formulation challenges around taste, texture and stability. India's market is also beginning to see novel formats: in June 2026, Bayer launched Alka-Seltzer in India as an effervescent powder sachet with probiotic support, illustrating the movement toward differentiated digestive-health formats.

India Antacids Market By Indication • Gastroesophageal Reflux Disease (GERD) is a significant driver of India's acid-control market. The Indian Society of Gastroenterology states that reported GERD prevalence in India ranges from 7.6% to 30%, with most population studies reporting prevalence below 10%. A community-based study in Vellore involving 6,174 adults found symptomatic GERD in 8.2% of participants, with prevalence substantially higher in urban residents than rural residents.
• Heartburn is one of the strongest consumer self-care indications because the symptom is readily recognizable and frequently prompts treatment without a formal diagnosis. A northern Indian rural study of 2,774 adults found that 10.7% met its GERD definition based on heartburn occurring more than twice weekly. The same study recorded varying weekly and daily heartburn frequencies, demonstrating the importance of symptom frequency when differentiating occasional self-treatment from persistent disease.
• Peptic ulcer represents a more clinically managed indication than routine heartburn. Antacids can reduce acid-related discomfort, but they do not address underlying causes such as H. pylori infection or medication-associated ulceration. PPIs and cause-directed treatment therefore have a more important therapeutic role for diagnosed ulcers. India's National Formulary lists aluminium hydroxide + magnesium hydroxide preparations among treatments indicated for peptic ulcers, heartburn and dyspepsia.
• Others include dyspepsia, acid indigestion, epigastric discomfort, gastritis-related symptoms and post-meal digestive discomfort. These complaints are important because Indian consumers may initially interpret upper-GI symptoms as ordinary acidity rather than as a specific gastrointestinal disorder. In a southern Indian population study of 1,072 participants, 26.4% reported heartburn and 18.1% reported acid regurgitation at some point assessed by the study questionnaire, illustrating the broader symptom population surrounding diagnosed GERD.

India Antacids Market By Distribution Channel • Retail pharmacies remain strategically important because consumers commonly approach pharmacies for symptom-based treatment and can select between antacids, H2 antagonists and PPIs. India's distinction between prescription and non-prescription medicines creates different levels of accessibility depending on the specific product. The strong self-care component of Indian gastrointestinal treatment makes pharmacist recommendation particularly relevant.
• Hospital pharmacies serve a more clinically supervised segment involving patients with diagnosed GERD, peptic ulcers, reflux complications and other gastrointestinal disorders. Their demand is therefore more influenced by physician diagnosis, hospital formularies and treatment protocols than by spontaneous OTC purchasing. PPIs and other prescription therapies are especially relevant in this channel.
• Online pharmacies / E-commerce provide convenience for repeat purchases and enable consumers to compare brands, formulations and pack sizes before ordering. The channel is particularly suitable for familiar OTC gastrointestinal products because consumers can reorder products they have previously used. Regulatory controls surrounding medicine sale and prescription status remain important when evaluating online distribution.
• Pharmacy-led self-medication is a particularly distinctive feature of the Indian environment. A systematic review and meta-analysis covering 17 studies and 10,248 participants examined self-medication practices across India, demonstrating the breadth of this behaviour nationally. In a separate community study of 400 participants, 17% reported antacids among the drug categories used for self-medication, while heartburn accounted for 13% of reported self-medication indications.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Antacids Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Class
• Acid Neutralizers
• Proton Pump Inhibitors (PPIs)
• H2 Antagonists
• Pro-Motility Agents
• Combination Formulations

By Dosage Form
• Tablets & Chewables
• Liquid Suspensions
• Powders
• Gels & Syrups
• Gummies & Other

By Indication
• Gastroesophageal Reflux Disease
• Heartburn
• Peptic Ulcer
• Others

By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies / E-Commerce